Skip to main content
Premium Trial:

Request an Annual Quote

Inscripta Raises $125M in Series D Financing Round

NEW YORK – Gene editing company Inscripta announced on Tuesday that it has raised $125 million in a Series D financing round.

Paladin Capital Group led the round, with support from existing investors and new investors JS Capital Management and Oak HC/FT. The company said it has now raised $259.5 million — its Series C round raised a total of $105.5 million after two expansions.

Inscripta said it plans to use the new funds to accelerate the development of applications for its Onyx Digital Genome Engineering platform, as well as for commercialization of the platform. The company unveiled the platform in June, calling it the first automated benchtop instrument that can write genomic modifications into any location within the genome in a rationally controlled and precise manner, with no random side effects.

"We're introducing single-cell writing technology," Inscripta CEO Kevin Ness said at the time.

In a statement on the new funding round, Ness said the additional financing will allow the company to meet the anticipated need for its platform.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.